Drug intelligence / Profile preview

CollaFusion

Development stage: Unknown
Lead developer: Glamderma
Modality: Recombinant Proteins and Enzymes
Administration: Intradermal, Subcutaneous

Overview

CollaFusion is a commercial medical aesthetic product marketed by Glamderma, primarily utilized as a skin booster for collagen support and volume augmentation. It is designed for intradermal or subcutaneous injection to improve skin elasticity, hydration, and structural integrity. As a finished aesthetic product rather than an investigational drug candidate, it typically functions by delivering exogenous collagen or stimulating endogenous collagen production within the dermal matrix. It is used in cosmetic procedures to address signs of aging, such as fine lines and loss of facial volume, by providing a scaffold for tissue regeneration and enhancing fibroblast activity.

Brand names: CollaFusion

Beyond the preview

Go deeper on CollaFusion.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CollaFusion.

Explore the full profile